NICE Affirms Guidance Denying Coverage Of Sequential TNF Inhibitors In RA
This article was originally published in The Pink Sheet Daily
Executive Summary
Makers of Humira, Enbrel and Remicade had appealed a negative 2006 appraisal, prompting a second look by UK health care agency.
You may also be interested in...
FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.
FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.
NICE Says No To Covering Bristol’s Orencia For Rheumatoid Arthritis
Bristol will file an appeal to the decision within 10 working days, the firm tells “The Pink Sheet” DAILY.